ResearcherWenzhou Medical UniversityActive in the last 2 years

Haihua Gu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-2154-9900; OpenAlex author ID A5025326035. Sources: OpenAlex.

Their work

Papers: 2 (first author 0, last author 1)
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 3

Papers, trials and grants by year

2022: 1 paper · 2023: none · 2024: none · 2025: none · 2026: 1 paper

Papers 2

Gomisin G Inhibits Pancreatic Cancer Cell Growth by Promoting YAP Degradation. Co-author DOI 10.1002/fsn3.72111 ↗
Therapeutic effect of a MUC1-specific monoclonal antibody-drug conjugates against pancreatic cancer model. Last author DOI 10.1186/s12935-022-02839-w ↗

Closest collaborators

The 3 strongest of 3 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Guang Jer Wu · 2 shared papers, 2022–2026 · strength 0.43
- Paper Gomisin G Inhibits Pancreatic Cancer Cell Growth by Promoting YAP Degradation. DOI 10.1002/fsn3.72111 ↗
- Paper Therapeutic effect of a MUC1-specific monoclonal antibody-drug conjugates against pancreatic cancer model. DOI 10.1186/s12935-022-02839-w ↗
Lan Li · 2 shared papers, 2022–2026 · strength 0.43
- Paper Gomisin G Inhibits Pancreatic Cancer Cell Growth by Promoting YAP Degradation. DOI 10.1002/fsn3.72111 ↗
- Paper Therapeutic effect of a MUC1-specific monoclonal antibody-drug conjugates against pancreatic cancer model. DOI 10.1186/s12935-022-02839-w ↗
Jiawei Cao · 1 shared paper, 2022 · strength 0.15
- Paper Therapeutic effect of a MUC1-specific monoclonal antibody-drug conjugates against pancreatic cancer model. DOI 10.1186/s12935-022-02839-w ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.